What Progor Treats: Main Uses

Progor is authorized for the management of a specified chronic inflammatory condition in the adult target population. The established therapeutic use is centered on addressing the progression of the disease and supports disease control when administered according to the recommended regimen.

In clinical trials, Progor has shown data that may lead to improved clinical outcomes for individuals with the condition. It is also indicated for the treatment of related severe symptoms associated with the specified condition, particularly when alternative standard therapy has been deemed insufficient to achieve adequate symptom management.

All therapeutic claims, including the precise wording of the indications, are subject to rigorous assessment to ensure that the benefit-risk balance is firmly established for the patient group. This detailed evaluation of a medicine's use is outlined in official documentation for marketing authorization applications.

Quick Facts: Progor Therapeutic Domain

• Main Use: Management of a specified chronic inflammatory condition.
• Action: Supports disease control and may lead to improved clinical outcomes.
• Specific Indication: Treatment of severe symptoms associated with the condition.

Regulatory References

1. EMA therapeutic overview

Official Eligibility and Contraindications

Regulatory agencies define specific patient populations that are strictly prohibited from using Progor (diltiazem hydrochloride) and others that require mandatory caution and monitoring. This information is based solely on official prescribing labels.

Absolute Contraindications (Must Not Use)

Progor is contraindicated for patients presenting with the following conditions, as stated in regulatory documents:

• Severe Cardiac Conduction Defects: Sick sinus syndrome or second-/third-degree AV block, unless a functioning ventricular pacemaker is present.
• Circulatory Instability: Severe hypotension (e.g., systolic blood pressure less than 90 mm Hg) or Cardiogenic Shock.
• Specific Arrhythmias: Atrial fibrillation or flutter associated with an accessory bypass tract (such as Wolff-Parkinson-White syndrome).
• Acute Heart Conditions: Acute myocardial infarction with pulmonary congestion.
• Hypersensitivity: Known sensitivity to the drug or its components.

Restricted or Conditional Use

Use of Progor requires caution and close monitoring in specific populations:

Interactions with other medicines and products

The interaction profile of Progor is significantly determined by its metabolism via the cytochrome P450 enzyme CYP3A4 and its transport by P-glycoprotein (P-gp). Concomitant use with other medicinal products can alter the concentrations of Progor or the co-administered drug, necessitating specific clinical management based on regulatory documentation.

Documented Interaction Categories

Official regulatory documents classify the combination with strong inducers as contraindicated due to the risk of reduced efficacy. Conversely, combinations with strong inhibitors require careful management, dose modification, and close observation due to the risk of increased exposure to Progor.

Progor (Diltiazem) exerts its effects through a dual mechanism defined by the blockade of L-type voltage-gated calcium channels (CaV 1.2) in cardiovascular tissue. This non-dihydropyridine mechanism provides a balanced influence on both the heart's electrical system and the muscle tone of the arteries.

Modulating Cardiac Electrical Conduction

This action involves the drug's direct effect on the Sinoatrial (SA) and Atrioventricular (AV) nodes, the specialized tissues that generate and conduct the heart's electrical impulse. By binding to and blocking the calcium channels in these cells, the drug initiates an electrophysiological cascade that results in negative chronotropy (slowing of heart rate) and negative dromotropy (slowing of conduction velocity). This mechanism directly modifies impulse generation and transmission, adjusting the activity within the cardiac electrical pathway.

Regulating Vascular Tone and Contractile Force

This domain addresses the mechanical consequences of the drug's action on the muscle tissues of the heart and blood vessels. In the Vascular Smooth Muscle (VSM) cells of the arteries, channel blockade restricts calcium necessary for contraction, causing vasodilation and lowering Systemic Vascular Resistance (SVR). Simultaneously, the blockade produces a negative inotropic effect on the heart muscle, reducing its contractile force. This combined effect results in a reduction of cardiac workload and influences the energetic balance within the myocardium. The negative inotropic effect physiologically constrains its application when there is severely reduced baseline myocardial contractility.

How to Use Progor: Official Administration Guidelines

Progor (Diltiazem hydrochloride) is administered through either oral or intravenous (IV) routes, with the specific route and dosage form dictated by the required therapeutic approach. Oral administration is used for chronic management, while the IV solution is reserved for acute, monitored settings.

Administration Patterns and Dosing

Special Procedural Constraints

The integrity of the medication's controlled-release mechanism must be preserved; therefore, extended-release capsules or tablets must not be crushed, divided, or chewed. For specific patient populations, such as older adults or individuals with hepatic or renal impairment, therapy is generally initiated at a lower oral starting dose (e.g., 120 mg once daily), followed by slow dose titration. The safety and official dosing for the pediatric population have not been established.

Research evidence / Overview of studies for Progor

Evidence for Progor in Managing High Blood Pressure (Hypertension)

Research for Progor in managing high blood pressure primarily involved Randomized Controlled Trials (RCTs) conducted over short and intermediate timeframes in adults with essential hypertension. These studies was studied for measuring systolic and diastolic blood pressure (BP), often compared to an inactive substance (placebo). Researchers focused on monitoring 24-hour BP profiles and tracking the proportion of individuals whose BP measurements fell within predefined ranges during the study period. Studies reported patterns where measurements of blood pressure changed in the observed populations. Some long-term observational research has also been used to provide context on the measurements observed over extended periods of chronic use. What remains uncertain is the data available for long-term clinical outcomes, such as the prevention of non-fatal stroke or heart attack, when compared against all other major classes of blood pressure medication over several decades.

Evidence for Progor in Supporting Chronic Stable Angina

The research base for chronic stable angina largely consists of Randomized Controlled Trials (RCTs) where Progor was evaluated in adults with the specified condition. These trials explored functional outcomes rather than long-term event prevention. Researchers examined outcomes reflecting daily functioning or activity level, such as the time an individual could spend on an exercise treadmill before discomfort occurred. Studies also monitored patient-reported outcomes tracking the weekly frequency of anginal episodes and the need for relief medications. Findings describe patterns observed in the studies including measured changes in the total exercise tolerance time observed in individuals receiving the medication during stress tests. A key gap is that the data are mostly related to these short-term functional measures.

Evidence for Progor in Acute Heart Rhythm Control (Atrial Fibrillation/Flutter)

Progor was evaluated in acute care settings, typically for adults presenting with Atrial Fibrillation or Atrial Flutter associated with a rapid ventricular rate. Research examined outcomes describing episodic or acute changes in the heart’s rhythm patterns. Studies primarily monitored physiological strain or stress by measuring the rate of the lower heart chambers at specific short intervals following administration. Findings describe patterns observed in the studies where the ventricular rate typically changed into the target range shortly after intravenous administration. The research provides limited specific insight into the subsequent clinical outcomes immediately following acute rate control in a highly heterogeneous acute-care population.

Research on Topical Progor for Pain and Healing of Chronic Anal Fissure

Research explored the use of a topical formulation of Progor in adults with chronic anal fissures. The evidence tracked two main axes: outcomes related to physical discomfort (pain scores) and fissure healing rates. Studies report how symptoms evolved in the observed populations, with findings describing measured shifts in pain severity reported by individuals. However, the data for fissure healing measurements were mixed and sometimes only marginally different from the control group in some reports. The evidence quality varies across studies for this application, and sample sizes were modest in some key RCTs.

Progor (diltiazem hydrochloride) must be stored and discarded according to specific regulatory requirements for both oral and injectable forms.

Storage Conditions

Oral solid dosage forms (tablets/capsules) must be stored at Controlled Room Temperature, which ranges from 20^circ to 25 C (68^circ to 77 F), with permitted excursions up to 30 C (86 F). The medication must be kept in its original container, tightly closed, and dispensed in a light-resistant container to avoid excessive heat and moisture. All forms of Progor must be kept out of the sight and reach of children.

Stability and Handling

The injectable solution requires protection from freezing. Once diluted for continuous infusion, the solution is stable for 24 hours at controlled room temperature or 48 hours under refrigeration (2^circ to 8 C) and any unused portion of single-dose vials must be discarded.

Disposal Instructions

Expired or unused Progor should be disposed of using a drug take-back program or mail-back service, which is the FDA's preferred method. If these options are unavailable, the medicine must be mixed with an undesirable substance (like coffee grounds or dirt), sealed in a container, and placed in the household trash. The medication must not be flushed down a toilet or sink.